ViaLase, a clinical-stage medical technology company focused on addressing unmet needs in conventional glaucoma treatment, announced that it has closed a Series C financing, raising about $40 million in gross proceeds. The funding was led by a new investor and supported by current investors, including Venture Investors Health Fund, Arboretum Ventures, and Falcon Vision, an ophthalmology investment platform supported by KKR.
The proceeds from this round of funding will ensure the continued advancement of clinical, regulatory, and commercial milestones of the company’s ViaLase Laser. If approved, the ViaLase Laser will be the first femtosecond laser to treat primary open-angle glaucoma (POAG).
ViaLase’s Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance for delivering a noninvasive glaucoma treatment called femtosecond laser image-guided high-precision trabeculotomy or FLigHT. And the novel FLigHT procedure will provide physicians with precision and visibility when creating channels in the trabecular meshwork (TM) to lower intraocular pressure (IOP) through a noninvasive, nonsurgical approach.
KEY QUOTES:
“ViaLase’s innovative approach to glaucoma management has the potential to elevate the standard of care for glaucoma patients around the world. We have strongly believed in ViaLase’s proven leadership, brilliant team, and pioneering technology since we wrote the first seed check to back the team.”
– Jim Adox, Executive Managing Director, Venture Investors
“The strong support from our investors validates the potential of the ViaLase Laser to enhance the current treatment paradigm for the millions of patients living with glaucoma. We are preparing to embark on a new phase in our company’s evolution—commercialization —and are incredibly fortunate to have the support, resources, financial backing and counsel of such a high-caliber group of investors.”
– Tibor Juhasz, PhD, Founder and Chief Executive Officer, ViaLase
